Seroflo represents a significant advancement in the management of persistent asthma and COPD, combining two established therapeutic agents into a single, convenient inhaler. This fixed-dose combination therapy synergistically addresses both the inflammatory and bronchoconstrictive components of obstructive airway diseases. By delivering a corticosteroid and a long-acting bronchodilator simultaneously, Seroflo offers superior symptom control, reduced exacerbation frequency, and improved quality of life for appropriate patients. Its optimized delivery system ensures consistent medication deposition throughout the bronchial tree while minimizing systemic exposure.

Features

• Contains fluticasone propionate (corticosteroid) and salmeterol xinafoate (long-acting beta2-agonist) in precise therapeutic ratios
• Available in multiple strength combinations to accommodate varying disease severity and patient needs
• Utilizes hydrofluoroalkane (HFA) propellant with minimal environmental impact
• Features a dose counter to track remaining medication and ensure treatment adherence
• Designed with ergonomic mouthpiece for optimal inhalation technique
• Delivers consistent micronized particles for deep lung deposition
• Manufactured under strict pharmaceutical quality control standards
• Provided with child-resistant cap for safety

Benefits

• Provides comprehensive asthma control by addressing both inflammation and bronchoconstriction
• Reduces frequency and severity of asthma exacerbations and emergency department visits
• Improves lung function measurements (FEV1) within the first treatment week
• Enables reduction of oral corticosteroid requirements in severe asthma cases
• Offers convenient twice-daily dosing regimen supporting long-term adherence
• Minimizes the need for rescue medication use through proactive symptom control

Common use

Seroflo is indicated for the regular treatment of asthma where use of a combination product is appropriate, specifically for patients not adequately controlled on inhaled corticosteroids and “as needed” short-acting inhaled beta2-agonists, or patients already controlled on both inhaled corticosteroids and long-acting inhaled beta2-agonists. It is also indicated for symptomatic treatment of patients with severe COPD (FEV1 < 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy. The medication is not intended for relief of acute bronchospasm and should not be used as a rescue medication.

Dosage and direction

For asthma treatment in adults and adolescents 12 years and older: The recommended dosage is two inhalations twice daily (morning and evening, approximately 12 hours apart). The strength should be individualized based on disease severity, with typical starting doses being Seroflo 100/50 or 250/50 (fluticasone/salmeterol mcg per inhalation). For COPD: The recommended dosage is two inhalations of Seroflo 250/50 twice daily. Patients should be instructed on proper inhalation technique, including shaking the inhaler well before each use, exhaling fully away from the mouthpiece, placing the mouthpiece between lips, inhaling deeply and steadily while pressing the canister, holding breath for 10 seconds, and waiting 30-60 seconds before the second inhalation. The mouth should be rinsed with water after each use to reduce the risk of oropharyngeal candidiasis and systemic absorption.

Precautions

Patients should be advised that Seroflo is not a rescue medication and does not replace fast-acting bronchodilators for acute symptoms. Caution is recommended in patients with tuberculosis, fungal, bacterial, viral, or parasitic infections, or ocular herpes simplex. Systemic effects of corticosteroids may occur, particularly at high doses and over prolonged periods, including adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract, and glaucoma. Patients should be monitored for increased bronchial hyperactivity and should not stop therapy abruptly. Paradoxical bronchospasm may occur, requiring alternative therapy. Hypokalemia and hyperglycemia may occur with high doses, particularly in acute severe asthma. Cardiovascular effects such as increases in pulse rate and blood pressure may be seen. Patients should be advised to seek medical attention if short-acting bronchodilator use increases or becomes less effective.

Contraindications

Seroflo is contraindicated in patients with hypersensitivity to fluticasone propionate, salmeterol xinafoate, or any component of the formulation. It should not be used for the treatment of acute asthma episodes or status asthmaticus. The product is contraindicated as primary treatment in patients with significantly worsening or acutely deteriorating asthma. Use is contraindicated in patients with known severe cardiovascular disorders, including arrhythmias, severe coronary artery disease, and uncontrolled hypertension. The combination should not be used with other long-acting beta2-agonists or with medications containing strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole) due to increased systemic corticosteroid exposure and cardiovascular risk.

Possible side effects

Common side effects (≥1/100 to <1/10) include: headache, throat irritation, hoarseness/dysphonia, oral candidiasis, cough, palpitations, tremor, and nausea. Uncommon side effects (≥1/1,000 to <1/100) may include: skin reactions, muscle cramps, anxiety, sleep disturbances, tachycardia, and hypokalemia. Rare side effects (≥1/10,000 to <1/1,000) include: angioedema, anaphylactic reactions, bronchospasm, glaucoma, cataract, and psychiatric effects including depression and behavioral changes. Very rare side effects (<1/10,000) include: cardiac arrhythmias, atrial fibrillation, ventricular extrasystoles, and hypertension. Systemic corticosteroid effects may occur with high doses, including adrenal suppression, reduction in bone mineral density, and growth retardation in children.

Drug interaction

Concomitant administration with strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, clarithromycin) is contraindicated due to increased systemic exposure to fluticasone and risk of systemic corticosteroid effects. Beta-blockers may antagonize the bronchodilating effects of beta-agonists and produce severe bronchospasm in asthmatic patients. Concomitant use with other beta-adrenergic drugs may potentiate sympathetic effects. Diuretics, corticosteroids, and xanthine derivatives may enhance the hypokalemic effect of beta2-agonists. ECG changes and/or hypokalemia that may result from non-potassium sparing diuretics can be acutely worsened by beta-agonists. Monoamine oxidase inhibitors and tricyclic antidepressants may potentiate the cardiovascular effects of beta-agonists.

Missed dose

If a dose is missed, patients should take it as soon as remembered unless it is almost time for the next dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Patients should never take a double dose to make up for a missed one. Maintaining regular dosing is important for optimal disease control, but occasional missed doses are unlikely to significantly affect overall treatment efficacy. Patients should contact their healthcare provider if multiple doses are missed or if they have questions about dosing schedule adjustments.

Overdose

Overdose may produce symptoms consistent with beta2-agonist overdose, including tachycardia, tremor, headache, muscle cramps, palpitations, nausea, dizziness, weakness, and hypokalemia. Fluticasone propionate overdose is unlikely to produce acute problems, but chronic overdose may lead to systemic corticosteroid effects. Treatment should be supportive and symptomatic. Cardiac monitoring is recommended in cases of significant overdose. Serum potassium levels should be monitored. Consideration should be given to discontinuation of Seroflo and implementation of appropriate symptomatic therapy. Dialysis is not appropriate treatment for overdose with this combination product.

Storage

Store at room temperature between 15°C and 30°C (59°F and 86°F). Do not freeze. Keep the canister away from direct heat or sunlight. Store with the mouthpiece down. Keep out of reach of children. The inhaler should be discarded 30 days after removal from the foil pouch or when the dose counter reads “0,” whichever comes first. Do not puncture or incinerate the canister, even when apparently empty. The product should be protected from moisture and should not be stored in damp places such as bathrooms.

Disclaimer

This information is provided for educational purposes only and does not constitute medical advice. Seroflo is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual patient needs may vary, and treatment decisions should be made in consultation with a physician who can assess the specific clinical situation. The complete prescribing information should be consulted before initiating therapy. Patients should not adjust their dosage or discontinue medication without medical supervision.

Reviews

Clinical studies demonstrate that Seroflo provides significantly better asthma control compared to monotherapy with inhaled corticosteroids alone. In randomized controlled trials involving over 3,000 patients, Seroflo showed superior improvement in lung function (mean increase in FEV1 of 0.15-0.25 L compared to baseline), reduced exacerbation rates by 25-40%, and improved quality of life scores. Patients reported better symptom control and reduced rescue medication use. Pulmonary specialists note the convenience of combination therapy and the reliable delivery system. Some patients report initial throat irritation that typically resolves with continued use and proper rinsing technique. The dose counter is frequently cited as a valuable feature for adherence monitoring. Long-term studies confirm maintained efficacy with appropriate dosing adjustments based on disease control status.